Pharmacological characterization of a structural hybrid P2X7R antagonist using ATP and LL-37
- 1 January 2022
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 914, 174667
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (APP1154692)
This publication has 40 references indexed in Scilit:
- Physiological Relevance of LL-37 Induced Bladder Inflammation and Mast CellsJournal of Urology, 2013
- Many ways to dilate the P2X7 receptor poreBritish Journal of Pharmacology, 2011
- Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor‐expressing cells: implications for its therapeutic actionBritish Journal of Pharmacology, 2011
- Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeabilityAmerican Journal of Physiology-Cell Physiology, 2011
- Mechanism of action of species‐selective P2X7receptor antagonistsBritish Journal of Pharmacology, 2009
- The Human Cathelicidin LL-37 Modulates the Activities of the P2X7 Receptor in a Structure-dependent MannerJournal of Biological Chemistry, 2008
- Negative and positive allosteric modulators of the P2X 7 receptorBritish Journal of Pharmacology, 2008
- Discovery of P2X7 receptor‐selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain statesBritish Journal of Pharmacology, 2007
- Direct labelling of the human P2X7receptor and identification of positive and negative cooperativity of bindingBritish Journal of Pharmacology, 2007
- pH-tuneable binding of 2′-phospho-ADP-ribose to ketopantoate reductase: a structural and calorimetric studyActa Crystallographica Section D Structural Biology, 2007